BiomX

BiomX is a microbiome company developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectalcancer (CRC), as well as bacteria that affect the appearance of the skin. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets.

The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology.